Blue Trust Inc. Sells 268 Shares of Penumbra, Inc. (NYSE:PEN)

Blue Trust Inc. lowered its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 52.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241 shares of the company’s stock after selling 268 shares during the quarter. Blue Trust Inc.’s holdings in Penumbra were worth $57,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New York State Teachers Retirement System boosted its stake in Penumbra by 0.4% in the 4th quarter. New York State Teachers Retirement System now owns 37,654 shares of the company’s stock worth $8,942,000 after purchasing an additional 148 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Penumbra by 39.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company’s stock worth $71,831,000 after buying an additional 85,284 shares in the last quarter. Savant Capital LLC lifted its holdings in shares of Penumbra by 8.0% in the fourth quarter. Savant Capital LLC now owns 2,981 shares of the company’s stock worth $708,000 after buying an additional 221 shares in the last quarter. 17 Capital Partners LLC bought a new position in shares of Penumbra during the fourth quarter worth $229,000. Finally, WCM Investment Management LLC purchased a new position in Penumbra during the fourth quarter valued at $13,451,000. Institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Canaccord Genuity Group increased their price target on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. StockNews.com upgraded Penumbra from a “hold” rating to a “buy” rating in a report on Thursday, February 20th. Morgan Stanley upped their price objective on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 19th. Finally, Oppenheimer began coverage on shares of Penumbra in a report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 target price for the company. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Penumbra currently has an average rating of “Moderate Buy” and an average target price of $292.64.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the sale, the director now directly owns 8,530 shares in the company, valued at approximately $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adam Elsesser sold 15,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,219 shares of company stock worth $4,426,439 over the last 90 days. Company insiders own 5.00% of the company’s stock.

Penumbra Stock Down 2.3 %

NYSE PEN opened at $281.15 on Wednesday. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of 826.92, a PEG ratio of 2.83 and a beta of 0.53. The company has a fifty day moving average of $260.58 and a two-hundred day moving average of $230.30.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. On average, analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.